Perthera and PanCAN Publish Pivotal Paper in Lancet Oncology Highlighting the Importance of Selecting Treatments Based on Tumor Mutations

This is the first study to demonstrate an overall survival benefit from precision medicine in pancreatic cancer patients. Patients who receive precision medicine live an average of one year longer than those who do not.